{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:49:00Z","timestamp":1779245340291,"version":"3.51.4"},"reference-count":88,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institutes of Health National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI180800"],"award-info":[{"award-number":["R21 AI180800"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Health National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI132244"],"award-info":[{"award-number":["R01 AI132244"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Health National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19 AI142790"],"award-info":[{"award-number":["U19 AI142790"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Health National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI180853"],"award-info":[{"award-number":["R21 AI180853"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["WO2022040238A2"],"award-info":[{"award-number":["WO2022040238A2"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["PCT\/US2021\/046380"],"award-info":[{"award-number":["PCT\/US2021\/046380"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Immunology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.it.2025.05.006","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:09:20Z","timestamp":1750723760000},"page":"512-524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Infusion of neutralization into Lassa vaccine design"],"prefix":"10.1016","volume":"46","author":[{"given":"Haoyang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn M.","family":"Hastie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica Ollmann","family":"Saphire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.it.2025.05.006_bb0005","first-page":"165","article-title":"Lassa fever natural history and clinical management","volume":"440","author":"Grant","year":"2023","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.it.2025.05.006_bb0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41579-022-00789-8","article-title":"Lassa fever \u2013 the road ahead","volume":"21","author":"Garry","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.it.2025.05.006_bb0015","first-page":"87","article-title":"Epidemiology of Lassa fever","volume":"440","author":"Bell-Kareem","year":"2023","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.it.2025.05.006_bb0020","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1038\/s41467-022-33112-3","article-title":"Predicting the evolution of the Lassa virus endemic area and population at risk over the next decades","volume":"13","author":"Klitting","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2025.05.006_bb0025","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1038\/s41591-024-03232-y","article-title":"Health and economic impacts of Lassa vaccination campaigns in West Africa","volume":"30","author":"Smith","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2025.05.006_bb0030","author":"World Health Organization"},{"key":"10.1016\/j.it.2025.05.006_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006187","article-title":"Lassa fever-induced sensorineural hearing loss: a neglected public health and social burden","volume":"12","author":"Mateer","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.it.2025.05.006_bb0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/trstmh\/traa011","article-title":"Lassa fever in pregnancy: a systematic review and meta-analysis","volume":"114","author":"Kayem","year":"2020","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.it.2025.05.006_bb0045","first-page":"75","article-title":"Lassa fever","volume":"262","author":"McCormick","year":"2002","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.it.2025.05.006_bb0050","author":"World Health Organization"},{"key":"10.1016\/j.it.2025.05.006_bb0055","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/infdis\/jix201","article-title":"A case of human Lassa virus infection with robust acute T-cell activation and long-term virus-specific T-cell responses","volume":"215","author":"McElroy","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.it.2025.05.006_bb0060","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1128\/JVI.01948-08","article-title":"Early and strong immune responses are associated with control of viral replication and recovery in Lassa virus-infected cynomolgus monkeys","volume":"83","author":"Baize","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.it.2025.05.006_bb0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s42003-020-01543-7","article-title":"Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques","volume":"4","author":"Baillet","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.it.2025.05.006_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1743-422X-8-205","article-title":"Pathogenesis of Lassa fever in cynomolgus macaques","volume":"8","author":"Hensley","year":"2011","journal-title":"Virol. J."},{"key":"10.1016\/j.it.2025.05.006_bb0075","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.3390\/v4112766","article-title":"Immune responses and Lassa virus infection","volume":"4","author":"Russier","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.it.2025.05.006_bb0080","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01367-20","article-title":"Severe human Lassa fever is characterized by nonspecific T-cell activation and lymphocyte homing to inflamed tissues","volume":"94","author":"Port","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.it.2025.05.006_bb0085","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11544","article-title":"Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits","volume":"7","author":"Robinson","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2025.05.006_bb0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw3163","article-title":"Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot","volume":"11","author":"Mateo","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2025.05.006_bb0095","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf6348","article-title":"A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains","volume":"13","author":"Mateo","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2025.05.006_bb0100","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/s41467-023-37050-6","article-title":"Rapid protection induced by a single-shot Lassa vaccine in male cynomolgus monkeys","volume":"14","author":"Mateo","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2025.05.006_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111094","article-title":"A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever","volume":"40","author":"Cross","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2025.05.006_bb0110","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa\u2013rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"Abreu-Mota","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2025.05.006_bb0115","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41541-024-00930-z","article-title":"Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease","volume":"9","author":"Scher","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.it.2025.05.006_bb0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s43856-024-00684-8","article-title":"The DNA-based Lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal Lassa fever","volume":"4","author":"Andrade","year":"2024","journal-title":"Commun. Med. (Lond.)"},{"key":"10.1016\/j.it.2025.05.006_bb0125","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1038\/s41467-023-41376-6","article-title":"A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection","volume":"14","author":"Ronk","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2025.05.006_bb0130","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.chom.2022.10.018","article-title":"Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection","volume":"30","author":"Brouwer","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.it.2025.05.006_bb0135","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41467-023-44534-y","article-title":"Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability","volume":"15","author":"Gorman","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2025.05.006_bb0140","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41541-021-00291-x","article-title":"ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge","volume":"6","author":"Fischer","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.it.2025.05.006_bb0145","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1016\/j.vaccine.2008.07.057","article-title":"Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates","volume":"26","author":"Lukashevich","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.it.2025.05.006_bb0150","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/vaccines12080858","article-title":"Preclinical safety assessment of the EBS-LASV vaccine candidate against Lassa fever virus","volume":"12","author":"Matassov","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.it.2025.05.006_bb0155","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1126\/science.282.5396.2079","article-title":"Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus","volume":"282","author":"Cao","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.it.2025.05.006_bb0160","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1126\/science.1252480","article-title":"Virus entry. Lassa virus entry requires a trigger-induced receptor switch","volume":"344","author":"Jae","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.it.2025.05.006_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008352","article-title":"High crossreactivity of human T cell responses between Lassa virus lineages","volume":"16","author":"Sullivan","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.it.2025.05.006_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020183","article-title":"Development of a new vaccine for the prevention of Lassa fever","volume":"2","author":"Geisbert","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.it.2025.05.006_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003736","article-title":"A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses","volume":"9","author":"Safronetz","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.it.2025.05.006_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105647","article-title":"Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials","volume":"114","author":"Cooper","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.it.2025.05.006_bb0185","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(23)00048-X","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial","volume":"401","author":"Tschismarov","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.it.2025.05.006_bb0190","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1080\/21645515.2019.1616499","article-title":"Immunogenicity of a protective intradermal DNA vaccine against Lassa virus in cynomolgus macaques","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.it.2025.05.006_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105673","article-title":"Mapping the antibody response to Lassa virus vaccination of non-human primates","volume":"114","author":"Enriquez","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.it.2025.05.006_bb0200","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/infdis\/jiab014","article-title":"Tetravalent rabies-vectored filovirus and Lassa fever vaccine induces long-term immunity in nonhuman primates","volume":"224","author":"Kurup","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.it.2025.05.006_bb0205","author":"US Food and Drug Administration"},{"key":"10.1016\/j.it.2025.05.006_bb0210","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nri891","article-title":"Antibodies, viruses and vaccines","volume":"2","author":"Burton","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2025.05.006_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112524","article-title":"Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies","volume":"42","author":"Perrett","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2025.05.006_bb0220","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nm.4396","article-title":"Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever","volume":"23","author":"Mire","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2025.05.006_bb0225","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.antiviral.2016.08.012","article-title":"Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies","volume":"133","author":"Cross","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.it.2025.05.006_bb0230","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq0991","article-title":"A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus","volume":"14","author":"Li","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2025.05.006_bb0235","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1126\/science.aam7260","article-title":"Structural basis for antibody-mediated neutralization of Lassa virus","volume":"356","author":"Hastie","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.it.2025.05.006_bb0240","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cell.2019.07.020","article-title":"Convergent structures illuminate features for germline antibody binding and pan-Lassa virus neutralization","volume":"178","author":"Hastie","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.it.2025.05.006_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110841","article-title":"Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies","volume":"39","author":"Enriquez","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2025.05.006_bb0250","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01278-22","article-title":"Neutralizing antibodies against Lassa virus lineage I","volume":"13","author":"Buck","year":"2022","journal-title":"MBio"},{"key":"10.1016\/j.it.2025.05.006_bb0255","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2304876120","article-title":"A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus","volume":"120","author":"Cross","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2025.05.006_bb0260","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2301061","article-title":"Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates","volume":"13","author":"Woolsey","year":"2024","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.it.2025.05.006_bb0265","article-title":"Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus","volume":"5","author":"Cross","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.it.2025.05.006_bb0270","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1111\/cts.13383","article-title":"A drug-disease model for predicting survival in an Ebola outbreak","volume":"15","author":"Toroghi","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.it.2025.05.006_bb0275","doi-asserted-by":"crossref","first-page":"12701","DOI":"10.1073\/pnas.221447598","article-title":"The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1\/S1P","volume":"98","author":"Lenz","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2025.05.006_bb0280","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41586-022-04429-2","article-title":"Structure and receptor recognition by the Lassa virus spike complex","volume":"603","author":"Katz","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.it.2025.05.006_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005418","article-title":"Acidic pH-induced conformations and LAMP1 binding of the Lassa virus glycoprotein spike","volume":"12","author":"Li","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.it.2025.05.006_bb0290","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.1073\/pnas.1803990115","article-title":"Structure of the Lassa virus glycan shield provides a model for immunological resistance","volume":"115","author":"Watanabe","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2025.05.006_bb0295","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1126\/science.aad2450","article-title":"Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer","volume":"351","author":"Lee","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.it.2025.05.006_bb0300","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abd4251","article-title":"Distinct conformational states of SARS-CoV-2 spike protein","volume":"369","author":"Cai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.it.2025.05.006_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009062","article-title":"Structural intermediates in the low pH-induced transition of influenza hemagglutinin","volume":"16","author":"Gao","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.it.2025.05.006_bb0310","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature07082","article-title":"Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor","volume":"454","author":"Lee","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.it.2025.05.006_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114708","article-title":"Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses","volume":"43","author":"Brouwer","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2025.05.006_bb0320","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1743-422X-3-41","article-title":"The role of single N-glycans in proteolytic processing and cell surface transport of the Lassa virus glycoprotein GP-C","volume":"3","author":"Eichler","year":"2006","journal-title":"Virol. J."},{"key":"10.1016\/j.it.2025.05.006_bb0325","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/vaccines1030262","article-title":"Enhanced efficacy of a codon-optimized DNA vaccine encoding the glycoprotein precursor gene of Lassa virus in a guinea pig disease model when delivered by dermal electroporation","volume":"1","author":"Cashman","year":"2013","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.it.2025.05.006_bb0330","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/1743-422X-7-306","article-title":"Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects","volume":"7","author":"Branco","year":"2010","journal-title":"Virol. J."},{"key":"10.1016\/j.it.2025.05.006_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005276","article-title":"Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection","volume":"11","author":"Sommerstein","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.it.2025.05.006_bb0340","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.virol.2010.10.011","article-title":"Glycosylation modulates arenavirus glycoprotein expression and function","volume":"409","author":"Bonhomme","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.it.2025.05.006_bb0345","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1128\/JVI.76.9.4199-4211.2002","article-title":"Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response","volume":"76","author":"Qui\u00f1ones-Kochs","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.it.2025.05.006_bb0350","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/imr.12512","article-title":"Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem","volume":"275","author":"Havenar-Daughton","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.it.2025.05.006_bb0355","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/s41586-022-05216-9","article-title":"Long-primed germinal centres with enduring affinity maturation and clonal migration","volume":"609","author":"Lee","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.it.2025.05.006_bb0360","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/imr.12860","article-title":"T follicular helper cells in germinal center B cell selection and lymphomagenesis","volume":"296","author":"Mintz","year":"2020","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.it.2025.05.006_bb0365","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-065X.2010.00937.x","article-title":"T cells and follicular dendritic cells in germinal center B-cell formation and selection: roles of T cells and FDCs in germinal centers","volume":"237","author":"Vinuesa","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.it.2025.05.006_bb0370","unstructured":"Saphire, E.O. et al. (2023) Engineered arenavirus glycoprotein compositions and methods of use thereof. 20230310568:A1"},{"key":"10.1016\/j.it.2025.05.006_bb0375","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn5315","article-title":"Experimental and computational understanding of pulsatile release mechanism from biodegradable core-shell microparticles","volume":"8","author":"Sarmadi","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.it.2025.05.006_bb0380","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41541-020-00219-x","article-title":"Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity","volume":"5","author":"M\u00fcller","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.it.2025.05.006_bb0385","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI131958","article-title":"Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death","volume":"130","author":"Cross","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.it.2025.05.006_bb0390","doi-asserted-by":"crossref","first-page":"13934","DOI":"10.1128\/JVI.79.22.13934-13942.2005","article-title":"A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses","volume":"79","author":"Lukashevich","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.it.2025.05.006_bb0395","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.vaccine.2011.12.134","article-title":"Evaluation of Lassa virus vaccine immunogenicity in a CBA\/J-ML29 mouse model","volume":"30","author":"Goicochea","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.it.2025.05.006_bb0400","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1016\/j.vaccine.2007.02.038","article-title":"A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity","volume":"25","author":"Carrion","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.it.2025.05.006_bb0405","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1128\/JVI.74.15.6777-6783.2000","article-title":"Effective vaccine for Lassa fever","volume":"74","author":"Fisher-Hoch","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.it.2025.05.006_bb0410","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.vaccine.2010.11.079","article-title":"Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs","volume":"29","author":"Jiang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.it.2025.05.006_bb0415","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.1128\/JVI.75.23.11677-11685.2001","article-title":"Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses","volume":"75","author":"Pushko","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.it.2025.05.006_bb0420","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00039-20","article-title":"A Lassa fever live-attenuated vaccine based on codon deoptimization of the viral glycoprotein gene","volume":"11","author":"Cai","year":"2020","journal-title":"MBio"},{"key":"10.1016\/j.it.2025.05.006_bb0425","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00578-24","article-title":"An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice","volume":"98","author":"Hashizume","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.it.2025.05.006_bb0430","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1038\/s41467-022-34008-y","article-title":"Dynamic HIV-1 spike motion creates vulnerability for its membrane-bound tripod to antibody attack","volume":"13","author":"Yang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2025.05.006_bb0435","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1038\/s41467-021-22867-w","article-title":"Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines","volume":"12","author":"He","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2025.05.006_bb0440","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41422-021-00490-0","article-title":"Structural basis for the different states of the spike protein of SARS-CoV-2 in complex with ACE2","volume":"31","author":"Yan","year":"2021","journal-title":"Cell Res."}],"container-title":["Trends in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490625001413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490625001413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T19:16:14Z","timestamp":1752606974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471490625001413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":88,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1471490625001413"],"URL":"https:\/\/doi.org\/10.1016\/j.it.2025.05.006","relation":{},"ISSN":["1471-4906"],"issn-type":[{"value":"1471-4906","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infusion of neutralization into Lassa vaccine design","name":"articletitle","label":"Article Title"},{"value":"Trends in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.it.2025.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}